1 Bladder Cancer 1 1 0 4 4 127 http://clinicaltrials.dfhcc.harvard.edu/trials/127 Randomized Study of Docetaxel +/- ZD6474 in Metastatic TCC In this research study the investigators are looking to see if the combination of docetaxel plus Zactima is effective in the treatment of metastatic transitional cell carcinoma (TCC). Docetaxel is a chemotherapy drug that kills cancer cells that are dividing. It is widely used in TCC. Zactima is a drug that is believed to stop new blood vessels from forming around cancer cells. The combination of docetaxel and Zactima has been studied in people with lung cancer and found to be helpful in killing cancer cells. Thus, this study is looking at people with TCC, to see if the combination of docetaxel plus Zactima is better or worse then docetaxel alone. Recruiting 1 Bladder Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/1-bladder-cancer Phase 2 341 http://clinicaltrials.dfhcc.harvard.edu/trials/341 Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma The purpose of this research study is to test the effectiveness of neoadjuvant chemotherapy in combination with pegfilgrastim followed by radical surgery in patients with muscle-invasive urothelial carcinoma. Recruiting 1 Bladder Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/1-bladder-cancer Phase 2 453 http://clinicaltrials.dfhcc.harvard.edu/trials/453 Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery RATIONALE: Drugs used in chemotherapy, such as fluorouracil, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This randomized phase II trial is studying two different chemotherapy and radiation therapy regimens to see how they work in treating patients with stage II or stage III bladder cancer that was removed by surgery. Recruiting 1 Bladder Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/1-bladder-cancer Phase 2 1223 http://clinicaltrials.dfhcc.harvard.edu/trials/1223 Phase II Trial of BIBW 2992 in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification. The primary objective of this trial is to estimate the objective response rate for patients with tumors harbouring EGFR and/or HER2 gene amplifications or EGFR activating mutations who will be treated with BIBW 2992. Recruiting 1 Bladder Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/1-bladder-cancer 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer 7 Endometrial/Uterine Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/7-endometrial-uterine-cancer